(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and ...
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles ...
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, ...
Melbourne, Australia The Government has expanded access to GSK's shingles vaccine, Shingrix, to cover individuals aged 18 ...
Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.
GSK has turned to Brooke Shields to get the message out about shingles vaccination. | GSK has turned to Brooke Shields to get ...
GSK touts co-administration data for RSV, shingles vaccines as narrowed CDC guidance threatens sales
In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...
A vaccine for the prevention of shingles in adults aged 50 and over and those aged 18 and over at increased risk KUALA LUMPUR ...
GSK has revised its annual vaccine sales forecast following new guidance on RSV from the CDC. But new evidence offers new ...
British drugmaker GSK (GSK.L), opens new tab said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback